7729 Stock Overview
A stem cell research and development company, develops and manufactures novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Steminent Biotherapeutics, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$22.70 |
| 52 Week High | NT$53.00 |
| 52 Week Low | NT$19.90 |
| Beta | 0 |
| 11 Month Change | 2.02% |
| 3 Month Change | -13.69% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7729 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.1% | 1.3% | -2.6% |
| 1Y | n/a | 0.1% | 25.6% |
Return vs Industry: Insufficient data to determine how 7729 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 7729 performed against the TW Market.
Price Volatility
| 7729 volatility | |
|---|---|
| 7729 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 4.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 7729's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 7729's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | n/a | www.steminent.com |
Steminent Biotherapeutics, Inc., a stem cell research and development company, develops and manufactures novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. The company focuses on Stemchymal portfolio of cell therapy research and development programs based on allogeneic stem cells that target neurodegenerative and other degenerative diseases. Its product pipeline includes various pre-clinical and clinical stage therapeutic programs for the treatment of spinocerebellar ataxia (PolyQ SCA), osteoarthritis of the knee, other neurodegenerative diseases, acute liver failure, and post-CPR syndrome.
Steminent Biotherapeutics, Inc Fundamentals Summary
| 7729 fundamental statistics | |
|---|---|
| Market cap | NT$1.27b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 7729 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7729 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7729 perform over the long term?
See historical performance and comparison